Research programme: neurodegenerative disorders therapeutics - NsGene

Drug Profile

Research programme: neurodegenerative disorders therapeutics - NsGene

Alternative Names: BrainRepair research project - NsGene; EC biodelivery programme - NsGene; ECB-PD; ECT-PD; Meteorin; Meteorin-like growth factors - NsGene; Ns G34; NsG 0301; NsG 33

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NsGene
  • Developer AlzeCure; NsGene; Sanofi Genzyme
  • Class Antibodies; Nerve growth factors
  • Mechanism of Action Glial cell line-derived neurotrophic factor modulators; Neuron stimulants; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Corticobasal degeneration; Motor neuron disease; Neurodegenerative disorders; Neuropathic pain; Parkinson's disease

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for preclinical development in Corticobasal-degeneration in Sweden (Intracerebral, Implant)
  • 28 Dec 2017 No recent reports of development identified for preclinical development in Corticobasal-degeneration in USA (Intracerebral, Implant)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Motor-neuron-disease in Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top